Physicians' Academy for Cardiovascular Education

Brigham and Women’s Transatlantic Dialogues on Controversies in Contemporary Cardiology

This special educational symposium explored controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic. American and European experts discussed novel insights from basic and translational cardiovascular science in the context of ongoing and future clinical studies.

Meeting Impression: Transatlantic dialogues on controversies in contemporary cardiology

BRIGHAM AND WOMEN’S TRANSATLANTIC DIALOGUES ON CONTROVERSIES IN CONTEMPORARY CARDIOLOGY

Dec. 6, 2016

This special educational symposium explored controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic.

The Development of ARNI: An example of Academic Industry Collaboration

BRIGHAM AND WOMEN’S TRANSATLANTIC DIALOGUES ON CONTROVERSIES IN CONTEMPORARY CARDIOLOGY

Dec. 4, 2016

Eugene Braunwald set out to illustrate the necessity and possible achievements of good collaboration between academia and industry, by taking the physiologic and clinical advances that led to the development of the first ARNi as an example.

PCSK9 therapeutics and cholesterol optimisation: on the the edge of an era?

BRIGHAM AND WOMEN’S TRANSATLANTIC DIALOGUES ON CONTROVERSIES IN CONTEMPORARY CARDIOLOGY

Dec. 4, 2016

In a dialogue, Jorge Plutzky and Erik Stroes explored to what extend we are at the edge of an era, considering the advent of PCSK9 inhibiting therapy. They discuss how this can impact clinical practice.

A new dawn for the treatment of heart failure? - Comorbidites and humility

BRIGHAM AND WOMEN’S TRANSATLANTIC DIALOGUES ON CONTROVERSIES IN CONTEMPORARY CARDIOLOGY

Dec. 4, 2016

Dr. Marc Pfeffer discusses how insights on the effect of antidiabetic drugs on CV outcomes has evolved over time, culminating in the benefit seen with empagliflozin on mortality and on heart failure. The latter benefit deserves more attention.

When do we remain with the devil we know (the vitamin K antagonists) … in atrial fibrillation? The case of “valvular atrial fibrillation”

Dec. 4, 2016

Raffaele De Caterina considers various forms of valvular disease that have been seen as a criterium not to use NOAC therapy for stroke prevention. Mitral stenosis may be an example that merits further study, as treatment may be indicated and safe.

How do we figure out the “optimal dose” of a NOAC for our patients?

BRIGHAM AND WOMEN’S TRANSATLANTIC DIALOGUES ON CONTROVERSIES IN CONTEMPORARY CARDIOLOGY

Dec. 4, 2016

Samuel Z Goldhaber considered the balance between the effect of NOACs on efficacy in preventing stroke and the risk of bleeding. How can NOACs best be dosed for an optimal balance?